
The Underdog in Pharma: Why Cytokinetics Is Grabbing Analysts’ Attention
Cytokinetics, Incorporated is recognized for its strength in muscle biology, actively developing therapies to enhance muscle performance. The company’s stock is viewed favorably by analysts, boasting a notable upside projection of nearly 52%. Aficamten, a key drug candidate, is set to potentially